Search clinical trials for: KD6005

Total 34 results

Shanghai Kanda Biotechnology Co., Ltd.

Recruiting

A Study of KD6005 in Healthy Participants and Participants With Rheumatoid Arthritis (RA)

Rheumatoid Arthritis

China
Shanghai Kanda Biotechnology Co., Ltd.

Recruiting

KD6001 in Combination With Anti-PD-1 Antibody in Patients With Advanced Melanoma

Melanoma

China
Dermavant Sciences GmbH

Completed

A Phase 2 Study of E6005 in Patients With Atopic Dermatitis

Atopic Dermatitis

Japan
Shanghai Kanda Biotechnology Co., Ltd.

Completed

Clinical Study of KD6001 in Advanced Solid Tumours

Solid Tumor

China
Dermavant Sciences GmbH

Completed

A Phase 1/2 Study of E6005 in Pediatric Subjects With Atopic Dermatitis

Atopic Dermatitis

Japan
Kymab Limited

Completed

A Study of Subcutaneous KY1005 in Healthy Volunteers

Immune System Diseases

United Kingdom
Kymab Limited

Completed

A Study of KY1005 in Healthy Volunteers

Immune System Diseases

Netherlands
Dermavant Sciences GmbH

Completed

A Study of E6005 in Japanese Patients With Atopic Dermatitis

Atopic Dermatitis

Japan
Kymab Limited

Completed

A Study of KY1005 in Patients With Moderate to Severe Atopic Dermatitis

Dermatitis, Atopic

Germany, Poland, Spain, United Kingdom
Pharmiva AB
CPS Research; Scandinavian Development Services AB; Key2Compliance AB

Active, not recruiting

Efficacy and Safety of D005 Vaginal Mousse on Bacterial Vaginosis

Bacterial Vaginosis | Vaginal | Microbiology

Sweden, United Kingdom
Kymab Limited
Sanofi

Completed

Study Testing Response Effect of KY1005 Against Moderate-to-Severe Atopic Dermatitis, The STREAM-AD Study (STREAM-AD)

Eczema | Atopic Dermatitis

United States, Australia, Bulgaria, Canada, Czechia, Germany, Hungary, Japan, Poland, Spain, Taiwan, United Kingdom
Pharmiva AB
Key2Compliance; Replior AB

Completed

A User Study With Vernivia® for Bacterial Vaginosis. (USV01)

Bacterial Vaginoses

Sweden
Fred Hutchinson Cancer Center
Sanofi

Recruiting

Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease

Chronic Graft Versus Host Disease

United States
Shanghai Kanda Biotechnology Co., Ltd.

Not yet recruiting

KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors

Other Solid Tumors | Advanced HCC

China
Kadmon Corporation, LLC
Quotient Sciences

Completed

Human Absorption, Distribution and Metabolism Study (hAME) [14C]-KD025 (KD025-108)

Fibrosis | Autoimmune Diseases

United Kingdom
Kadmon, a Sanofi Company

Terminated

Efficacy and Safety of Belumosudil in Subjects With Diffuse Cutaneous Systemic Sclerosis (dcSSC)

Diffuse Cutaneous Systemic Sclerosis

United States
Kadmon, a Sanofi Company

Completed

KD025 Hepatic Impairment Study With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment

Hepatic Impairment

United States
Kadmon, a Sanofi Company

Recruiting

Safety and Efficacy of Oral Belumosudil in Black or African American, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander Male and Female Participants Aged 12 Years and Above With Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy

Chronic Graft Versus Host Disease

United States
Kadmon, a Sanofi Company

Terminated

KD025 in Subjects With Diffuse Cutaneous Systemic Sclerosis

Diffuse Cutaneous Systemic Sclerosis | System; Sclerosis

United States
Kadmon Corporation, LLC

Completed

Phase 2, Open-label, Study of KD025 in Subjects With Psoriasis Vulgaris Who Failed First-line Therapy

Psoriasis Vulgaris

United States
Kadmon, a Sanofi Company

Completed

A Study to Determine the Effect of Multiple Oral Doses of SLx-2119 in Healthy Male Subjects

Immune System Disorder (Healthy Volunteer)

United States
Kadmon Corporation, LLC

Completed

A Phase 2, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Belumosudil in Subjects With Moderate/Severe Chronic Plaque Psoriasis

Chronic Plaque Psoriasis

United States
BioNova Pharmaceuticals (Shanghai) LTD.

Completed

Efficacy and Safety of BN101 in Subjects With Chronic Graft Versus Host Disease (cGVHD)

GVHD, Chronic

China
Kadmon Corporation, LLC

Completed

A Safety and Tolerability Study of Belumosudil (KD025) Treatment in Subjects With Moderately Severe Psoriasis Vulgaris

Psoriasis Vulgaris

United States
Kadmon, a Sanofi Company

Terminated

Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy

Chronic Graft-versus-host-disease

United States
Kadmon, a Sanofi Company

Completed

A Study to Determine the Effect of 500 mg Oral Dose of KD025 in Healthy Male and Post-menopausal Female Subjects

Immune System Disorder (Healthy Volunteer)

United States
Kadmon, a Sanofi Company

Completed

A Study to Determine the Effect of Multiple Oral Doses and Regimens of KD025 in Healthy Male and Post-menopausal Female Subjects

Immune System Disorder (Healthy Volunteer)

United States
Kadmon, a Sanofi Company

Completed

A Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Chronic Graft Versus Host Disease

Graft vs Host Disease

United States
Kadmon Corporation, LLC

Completed

A 2-Part, Phase 2 Open-label and Crossover Study of Belumosudil for Treatment of Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

United States
Randy Trumbower, PT, PhD

Not yet recruiting

Combining Low Oxygen Therapy and an Adenosine A2a Receptor Antagonist to Improve Functional Mobility After Spinal Cord Injury

Spinal Cord Injuries | Myelopathy

United States
Kadmon, a Sanofi Company

Completed

A Study to Assess the Effect of Oral Belumosudil on Inhibition of Various Proteins in the Fed State in Healthy Male Subjects

Immune System Disorder (Healthy Volunteers)

United States
Sanofi

Recruiting

A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease. (ROCKnrol-1)

Chronic Graft Versus Host Disease

Australia, Argentina, Belgium, Spain, Sweden, Czechia, United Kingdom, United States, Italy, Germany, Canada, Israel, Denmark, Brazil
Kadmon Corporation, LLC
Quotient Sciences

Completed

A Phase I Study to Evaluate the Taste of Belumosudil Oral Suspensions & Assess Relative Bioavailability

Healthy Volunteers

United Kingdom
Dana-Farber Cancer Institute
Sanofi; National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)

Chronic Graft Versus Host Disease | Lung Diseases | Bronchiolitis Obliterans | Bronchiolitis Obliterans Syndrome

United States

3

Subscribe